|
|
News Breaks
|
December 6, 2011
|
| 08:05 EDT |  | PPHM |
| theflyonthewall.com: | Peregrine's Bavituximab shows 50% improvement in overall tumor response rate | | Peregrine Pharmaceuticals announced preliminary results from a randomized Phase II trial showing a 50% improvement in overall tumor response rates (ORR) in non-small cell lung cancer (NSCLC) patients. Patients treated with bavituximab plus carboplatin and paclitaxel currently demonstrate an ORR of 39%, versus 26% in patients treated with carboplatin and paclitaxel alone. This preliminary analysis using RECIST guidelines included all 86 front-line, Stage IV NSCLC patients randomized in this Phase II trial. Peregrine plans to report on secondary endpoints, including median progression-free survival (PFS) and overall survival (OS) once reached during 2012. Bavituximab's therapeutic potential is being evaluated in three randomized Phase II trials in front-line NSCLC, second-line NSCLC, and front-line pancreatic cancer, as well as in four investigator-sponsored trials (ISTs) in additional oncology indications with clinical data from each study expected in 2012. :theflyonthewall.com |
|
|
News For PPHM From The Last 14 Days Check below for free stories on PPHM the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 21, 2012
|
| 09:00 EDT |  | PPHM |
| | 07:36 EDT | | PPHM |
|
|
|
|
|
Subscribe for More Information